Mathieu Lupien
Overview
Explore the profile of Mathieu Lupien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
8562
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Furlano K, Keshavarzian T, Biernath N, Fendler A, De Santis M, Weischenfeldt J, et al.
Int J Cancer
. 2025 Jan;
PMID: 39853587
Prostate cancer is a common malignancy that in 5%-30% leads to treatment-resistant and highly aggressive disease. Metastasis-potential and treatment-resistance is thought to rely on increased plasticity of the cancer cells-a...
2.
Lee J, Tao R, You Z, Haldipur P, Erickson A, Farooq H, et al.
Nat Genet
. 2025 Jan;
57(1):88-102.
PMID: 39753768
Transcription factors are frequent cancer driver genes, exhibiting noted specificity based on the precise cell of origin. We demonstrate that ZIC1 exhibits loss-of-function (LOF) somatic events in group 4 (G4)...
3.
Laisne M, Lupien M, Vallot C
Nat Rev Cancer
. 2024 Oct;
25(1):7-26.
PMID: 39414948
In the past decade, remarkable progress in cancer medicine has been achieved by the development of treatments that target DNA sequence variants. However, a purely genetic approach to treatment selection...
4.
Zhang K, Wei J, Zhang S, Fei L, Guo L, Liu X, et al.
Cell Chem Biol
. 2024 Sep;
31(11):1942-1957.e6.
PMID: 39232499
Paclitaxel-resistant triple negative breast cancer (TNBC) remains one of the most challenging breast cancers to treat. Here, using an epigenetic chemical probe screen, we uncover an acquired vulnerability of paclitaxel-resistant...
5.
Su P, Liu Y, Chen T, Xue Y, Zeng Y, Zhu G, et al.
Nat Genet
. 2024 Sep;
56(9):1890-1902.
PMID: 39227744
Functional genomic screens in two-dimensional cell culture models are limited in identifying therapeutic targets that influence the tumor microenvironment. By comparing targeted CRISPR-Cas9 screens in a two-dimensional culture with xenografts...
6.
Boutzen H, Murison A, Oriecuia A, Bansal S, Arlidge C, Wang J, et al.
Leukemia
. 2024 Aug;
38(10):2090-2101.
PMID: 39169113
The leukemia stem cell (LSC) compartment is a complex reservoir fueling disease progression in acute myeloid leukemia (AML). The existence of heterogeneity within this compartment is well documented but prior...
7.
Zhao S, Bootsma M, Zhou S, Shrestha R, Moreno-Rodriguez T, Lundberg A, et al.
Nat Genet
. 2024 Jul;
56(8):1689-1700.
PMID: 39020220
The impact of variations in the three-dimensional structure of the genome has been recognized, but solid cancer tissue studies are limited. Here, we performed integrated deep Hi-C sequencing with matched...
8.
Shrestha R, Chesner L, Zhang M, Zhou S, Foye A, Lundberg A, et al.
Cancer Res
. 2024 Jul;
84(18):3086-3100.
PMID: 38990734
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease that resists therapy targeting androgen signaling, the primary driver of prostate cancer. mCRPC resists androgen receptor (AR) inhibitors by amplifying AR...
9.
Johnston M, Lee J, Hu B, Nikolic A, Hasheminasabgorji E, Baguette A, et al.
Cell
. 2024 Jul;
187(18):4926-4945.e22.
PMID: 38986619
Posterior fossa group A (PFA) ependymoma is a lethal brain cancer diagnosed in infants and young children. The lack of driver events in the PFA linear genome led us to...
10.
Kohan A, Lupien M, Cescon D, Deblois G, Ventura M, Metser U, et al.
Eur J Nucl Med Mol Imaging
. 2023 Dec;
51(5):1261-1267.
PMID: 38095672
Purpose: Test the feasibility of an image-based method to identify taxane resistance in mouse bearing triple-negative breast cancer (TNBC) tumor xenografts. Methods: Xenograft tumor-bearing mice from paclitaxel-sensitive and paclitaxel-resistant TNBC...